[First NOAK antidote soon to be approved].
, .
H
H
Holzgreve
D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D000069604:Dabigatran / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D017277:Drug Approval; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D020521:Stroke / Q000517:prevention & control; D013997:Time Factors
D061067:Antibodies, Monoclonal, Humanized; C000594745:idarucizumab; D000069604:Dabigatran